Rumors of the Death of Biosimilars Have Been Greatly Exaggerated.
Publication
, Journal Article
Lyman, GH; Kuderer, N
Published in: Cancer Invest
2019
Duke Scholars
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
2019
Volume
37
Issue
8
Start / End Page
325 / 326
Location
England
Related Subject Headings
- United States
- Oncology & Carcinogenesis
- Humans
- Health Services Accessibility
- Health Care Reform
- Drug Costs
- Drug Approval
- Biosimilar Pharmaceuticals
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., & Kuderer, N. (2019). Rumors of the Death of Biosimilars Have Been Greatly Exaggerated. Cancer Invest, 37(8), 325–326. https://doi.org/10.1080/07357907.2019.1666515
Lyman, Gary H., and Nicole Kuderer. “Rumors of the Death of Biosimilars Have Been Greatly Exaggerated.” Cancer Invest 37, no. 8 (2019): 325–26. https://doi.org/10.1080/07357907.2019.1666515.
Lyman GH, Kuderer N. Rumors of the Death of Biosimilars Have Been Greatly Exaggerated. Cancer Invest. 2019;37(8):325–6.
Lyman, Gary H., and Nicole Kuderer. “Rumors of the Death of Biosimilars Have Been Greatly Exaggerated.” Cancer Invest, vol. 37, no. 8, 2019, pp. 325–26. Pubmed, doi:10.1080/07357907.2019.1666515.
Lyman GH, Kuderer N. Rumors of the Death of Biosimilars Have Been Greatly Exaggerated. Cancer Invest. 2019;37(8):325–326.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
2019
Volume
37
Issue
8
Start / End Page
325 / 326
Location
England
Related Subject Headings
- United States
- Oncology & Carcinogenesis
- Humans
- Health Services Accessibility
- Health Care Reform
- Drug Costs
- Drug Approval
- Biosimilar Pharmaceuticals
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis